The Recombinant Coagulation Factors market is a subset of the Hematological Drugs market, which includes drugs used to treat blood-related diseases. Recombinant Coagulation Factors are proteins used to treat bleeding disorders, such as hemophilia, von Willebrand disease, and other rare bleeding disorders. These drugs are used to replace or supplement the body's natural clotting factors, which are proteins that help the blood clot. Recombinant Coagulation Factors are produced in a laboratory using recombinant DNA technology, which allows for the production of large quantities of the proteins. The Recombinant Coagulation Factors market is highly competitive, with several major players. These include Novo Nordisk, Pfizer, Bayer, Biogen, and CSL Behring. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
